Home / Members/ Profile
Alison Fox-Robichaud
McMaster University
Hamilton , ON
Research Focus:

Alison Fox-Robichaud

Translational Biology Group (CCCTBG)

Dr. Fox-Robichaud (she/her) is a Professor of Medicine at McMaster University and a Critical Medicine Specialist, Director of Medical Education at Hamilton Health Sciences and Scientific Director of Sepsis Canada, a nationally funded research network. She is a scientist in the Thrombosis and Atherosclerosis Research Institute where she supervises undergraduate, graduate and postdoctoral trainees.

Her more than 125 peer-reviewed publications reflect a broad engagement in academic medicine including preclinical studies, translational biomarkers for diagnosis, clinical trials, and quality improvement. She has been honored nationally for her work in electronic early warning scores to prevent patient deterioration. Internationally, in 2018 the Global Sepsis Alliance awarded her an individual award for her sepsis leadership.

A leader in the critical care community, she is a past president of the Canadian Critical Care Society (CCCS) and a past chair of the Canadian Critical Care Examination board. Internationally, she is a member of Global Sepsis Alliance board, the advisory board of the International Society for Rapid Response Systems and the council of the World Federation of Intensive and Critical Care. She has an active presence on Twitter (@drfoxrob) that she uses to advocate for critical care and sepsis patients and on issues of equity, diversity, and inclusion.

Recent work

Damodara S, Arora J, Liaw PC, Fox-Robichaud AE, Selvaganapathy PR, on behalf of the Canadian Critical Care Translational Biology Group. (2022). Single-step measurement of cell-free DNA for sepsis prognosis using a thread-based microfluidic device. Microchim Acta. 189: 1-10.

Catenacci V, Sheikh F, Patel K, Fox-Robichaud AE. (2022). The prognostic utility of protein C as a biomarker for adult sepsis: a systematic review and meta-analysis. Crit Care. 26(21): 1-12.

Pook M, Zamir N, McDonald E, Fox-Robichaud AE. (2022). Chlorhexidine (di)gluconate locking device for central line infection prevention in intensive care unit patients: A multi-unit, pilot randomized controlled trial. Vascular Access. 16(1): 6-19.

Fiest KM, Krewulak KD, Brundin-Mather R, Leia MP, Fox-Robichaud A, Lamontagne F, Leigh JP, for Sepsis Canada. (2022). Patient, Public, and Healthcare Professional’s Sepsis Awareness, Knowledge, and Information Seeking Behaviors: A Scoping Review. Crit Care Med. 50: 1-5.

In my own words

I LOVE science. Curiosity drives me.